CD277, Fc-Fusion (IgG1) Avi-Tag Recombinant

Only %1 left
Catalog #
100073
As low as $145 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human CD277 (cluster of differentiation 277), encompassing amino acids 31-254. This construct contains a C-terminal Fc region of Human IgG1 fused to an Avi-Tag™. This protein was affinity purified.

Synonyms
Butyrophilin subfamily 3 member A1, BTN3A1, BTF5
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD277 (31-254-Fc(lgG1)-Avi)
Host Species/Expression System
HEK293
Purity

≥90%

Format
Aqueous buffer solution
Formulation
8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
MW
53 kDa + glycans
Amino Acids
31-254
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_007048
UniProt #
O00481
Tag(s)
C-terminal Avi-tag™
Background

CD277 (cluster of differentiation 277), also known as BTN3A (butyrophilin subfamily 3), belongs to the BTN family of proteins. CD277 is expressed in T and B cells, monocytes, dendritic and NK cells. It can bind to pAGs (phosphate antigen), stimulating Vγ9Vδ2 T cells, a T cell type mainly found in the peripheral blood which can target cancer cells. It is also found in many cancer types and can be used as a prognosis marker in ovarian, breast and bladder cancer, and pancreatic ductal adenocarcinoma. Its expression levels vary with the type of cancer, with breast cancer showing lower levels, while advanced ovarian cancer can present high protein expression. A deeper understanding of the role of CD277 in each cancer type may open new targeted therapeutic opportunities.

References

1. Wykes, M., et al., Journal of Leukocyte Biology, 2002 Oct; 72(4): 692-701.

2. Mukherjee, P., et al., Journal of Leukocyte Biology. 2004 Jan; 77(1): 90-99.